Drug intelligence / Profile preview

CTA-004

Development stage: Preclinical
Lead developer: CytoArm Biotechnology
Modality: Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTA-004 is an experimental Armed-T™ cell therapy being developed by CytoArm for the treatment of metastatic breast carcinoma. The therapy utilizes engineered T cells that are "armed" to specifically target and eliminate tumor cells expressing the Human Epidermal Growth Factor Receptor 2 (HER2). This approach combines the cytotoxic potential of T cells with the precision of targeted therapy, aiming to provide a novel treatment option for patients with HER2-positive metastatic breast cancer. As of the current pipeline status, the program is in the research stage.

Other names: CytoArm-HER2-Armed-T cell therapyCytoArm-HER-2-Armed-T cell therapyCytoArm-HER 2-Armed-T cell therapy

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on CTA-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTA-004.

Explore the full profile